ANI Pharmaceuticals, Inc. (ANIP)
ANIP moved a median of -0.03% 30 minutes after news, and +0.01% by the close. How ANIP actually reacts to news — the realized, point-in-time move the market made, measured across 499 labeled events over the last three years with zero look-ahead.
ANIP’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 44% | 497 |
| 30-min | -0.03% | 47% | 499 |
| 60-min | -0.13% | 42% | 499 |
| to close | +0.01% | 50% | 492 |
| Middle 50% of ANIP reactions | -0.50% to +0.42% |
|---|---|
| Median reaction (30-min) | -0.03% |
| Measured reactions | 499 |
Half of all ANI Pharmaceuticals, Inc. news events land between -0.50% and +0.42% at 30 minutes.
Reaction stats as of 2026-08-31. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How ANIP reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Analyst downgrades | 10 | +0.54% | 80% | +1.60% |
| Coverage initiations | 23 | +0.93% | 61% | -0.30% |
| Rating reiterations | 46 | +0.38% | 67% | +0.03% |
| Price-target raises | 16 | -0.23% | 44% | -0.77% |
Last 3 years, pulled 2026-08-31. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how ANIP ranks against every other measured name →
That’s how ANIP usually reacts — get an email when it moves on news →Email me when ANIP moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to ANIP's baseline. Nothing else.
Recent ANIP events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| ANI Pharmaceuticals to Present at September Investor Conferences | Press release | GlobeNewswire | -0.66% | -2.83% | |
| ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directors | Press release | GlobeNewswire | -0.74% | -1.51% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | -1.51% | |
| ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results | Press release | GlobeNewswire | -3.58% | +1.50% | |
| Form 10-Q ANI PHARMACEUTICALS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -3.58% | +1.50% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -3.58% | +1.50% | |
| ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET | Press release | GlobeNewswire | -0.65% | -1.76% | |
| Form S-8 ANI PHARMACEUTICALS INC | SEC filing · Form S-8 | SEC EDGAR | +0.56% | -1.76% | |
| ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Press release | GlobeNewswire | +0.29% | -2.10% | |
| ANI Pharmaceuticals Announces Positive Six-Month Topline Data from the Phase 4 Open-Label, Single-Arm SYNCHRONICITY Trial Evaluating Fluocinolone Acetonide Intravitreal Implant in Patients with Chronic Non-Infectious Uveitis | Press release | GlobeNewswire | +0.44% | -0.93% | |
| ANI Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference | Press release | GlobeNewswire | -0.89% | -0.54% | |
| Form 8-K ANI PHARMACEUTICALS INC For: May 21 | SEC filing · Form 8-K | SEC EDGAR | -0.04% | -0.10% | |
| Form 8-K ANI PHARMACEUTICALS INC For: May 13 | SEC filing · Form 8-K | SEC EDGAR | -0.06% | +3.48% | |
| ANI Pharmaceuticals Reports First Quarter 2026 Financial Results and Raises 2026 Financial Guidance | Press release | GlobeNewswire | -6.10% | -6.72% | |
| Form 10-Q ANI PHARMACEUTICALS INC For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -6.10% | -6.72% | |
| Form 8-K ANI PHARMACEUTICALS INC For: May 08 | SEC filing · Form 8-K | SEC EDGAR | -6.10% | -6.72% | |
| ANI Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 8, 2026, at 8:00 a.m. ET | Press release | GlobeNewswire | +0.73% | +0.98% | |
| ANI Pharmaceuticals Announces the FDA Approval and Launch of Pimozide Tablets with 180 Day CGT Exclusivity | Press release | GlobeNewswire | -0.04% | +0.90% | |
| ANI Pharmaceuticals Announces the Launch of Carbamazepine Extended-Release Capsules | Press release | GlobeNewswire | +0.67% | +0.46% | |
| Form ARS ANI PHARMACEUTICALS INC For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.17% | -2.22% | |
| Form DEF 14A ANI PHARMACEUTICALS INC For: Dec 31 | SEC filing · Form DEF | SEC EDGAR | -0.17% | -2.22% | |
| Form DEFA14A ANI PHARMACEUTICALS INC | SEC filing · Form DEFA14A | SEC EDGAR | -0.17% | -2.22% | |
| ANI Pharmaceuticals Announces FDA Approval and Launch of Isosorbide Mononitrate Tablet | Press release | GlobeNewswire | +0.16% | -2.60% | |
| ANI Pharmaceuticals Announces Publication of NEW DAY Clinical Trial Results in Ophthalmology | Press release | GlobeNewswire | -0.25% | +3.42% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Apr 01 | SEC filing · Form 8-K | SEC EDGAR | +0.16% | -2.60% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Mar 03 | SEC filing · Form 8-K | SEC EDGAR | -0.12% | +1.72% | |
| ANI Pharmaceuticals Reports Record Fourth Quarter and Full Year 2025 Financial Results and Reaffirms 2026 Financial Guidance | Press release | GlobeNewswire | -3.22% | -5.07% | |
| Form 10-K ANI PHARMACEUTICALS INC For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -3.22% | -5.07% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Feb 27 | SEC filing · Form 8-K | SEC EDGAR | -3.22% | -5.07% | |
| ANI Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.97% | +1.78% | |
| ANI Pharmaceuticals to Discuss Fourth Quarter and Full Year 2025 Financial Results on February 27, 2026, at 8:00 a.m. ET | Press release | GlobeNewswire | +0.33% | +0.73% | |
| ANI Pharmaceuticals Highlights Significant Growth in 2025, Provides 2026 Financial Guidance, and Outlines Strategic Priorities | Press release | GlobeNewswire | -1.76% | +2.49% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -0.27% | -2.43% | |
| ANI Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -0.90% | +1.79% | |
| ANI Pharmaceuticals Announces Formation of “FutureVision Advisory Council” to Help Strategically Guide Ophthalmology and Retina Franchise | Press release | GlobeNewswire | -0.44% | -2.67% | |
| ANI Pharmaceuticals Announces Board Transition | Press release | GlobeNewswire | -0.55% | +0.32% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Nov 24 | SEC filing · Form 8-K | SEC EDGAR | -0.55% | +0.32% | |
| ANI Pharmaceuticals to Present at the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +0.37% | +1.81% | |
| ANI Pharmaceuticals to Present at the Jefferies Global Healthcare Conference – London | Press release | GlobeNewswire | +0.00% | -2.46% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Nov 10 | SEC filing · Form 8-K | SEC EDGAR | -0.67% | +1.54% | |
| ANI Pharmaceuticals Reports Record Third Quarter 2025 Financial Results and Raises 2025 Guidance | Press release | GlobeNewswire | +4.56% | +5.42% | |
| Form 10-Q ANI PHARMACEUTICALS INC For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +4.56% | +5.42% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Nov 07 | SEC filing · Form 8-K | SEC EDGAR | +4.56% | +5.42% | |
| ANI Pharmaceuticals to Discuss Third Quarter 2025 Financial Results on November 7, 2025, at 8:30 a.m. ET | Press release | GlobeNewswire | +0.27% | -0.98% | |
| ANI Pharmaceuticals Announces NEW DAY Clinical Trial Results to be Presented in Late-Breaking Oral Presentation at the American Academy of Ophthalmology 2025 Meeting | Press release | GlobeNewswire | +0.49% | +1.85% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Sep 26 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -1.35% | |
| Form 8-K ANI PHARMACEUTICALS INC For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | -1.30% | -0.68% | |
| ANI Pharmaceuticals to Present at Upcoming Investor Conferences | Press release | GlobeNewswire | +0.31% | +1.74% | |
| ANI Pharmaceuticals Reports Record Second Quarter 2025 Financial Results and Raises 2025 Guidance | Press release | GlobeNewswire | +3.60% | +4.65% | |
| Form 10-Q ANI PHARMACEUTICALS INC For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +3.60% | +4.65% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the ANIP section they belong to.
Where else ANIP is measured.
ANIP earnings → · Analyst actions → · SEC filings →
Other Healthcare names, measured the same way
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Teligent, Inc. (TLGT) | 502 | -0.17% | 43% |
| Zealand Pharma A/S - American Depositary Shares (ZEAL) | 501 | 0.00% | 40% |
| ARGOS THERAPEUTICS (ARGS) | 498 | -0.22% | 39% |
| BIOANALYTICAL SYSTEMS (BASI) | 498 | 0.00% | 40% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not.
All Healthcare names, measured the same way →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is ANI Pharmaceuticals, Inc.'s median reaction calculated?
Every labeled ANIP news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 499 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 47% of ANIP's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-08-31.
Does ANIP's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.